Medexus Signs a Multiple Agreement with NXDC to Commercialize Gleolan for the Treatment of Glioma in the US
Shots:
- Under the terms of the new license, supply & distribution agreement, Medexus gets an exclusive right to commercialize Gleolan in the US complementing Medexus’ existing rights to Gleolan in Canada
- NXDC to receive upfront, milestones along with royalties & will be responsible to supply Gleolan to Medexus & will remain the sponsor of Gleolan’s NDA on file with the US FDA
- NXDC will continue the R&D activities including additional indications for Gleolan. Gleolan is the US FDA-approved optical imaging agent for patients with glioma as an adjunct for the visualization of malignant tissue during surgery. Gleolan is expected to receive the ODD from the US FDA by June 2024
Ref: Medexus | Image: Medexus
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
